Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
NeuroMolecular Medicine
Published in: NeuroMolecular Medicine 2-3/2017

01-09-2017 | Review Paper

Molecular Basis of Pediatric Brain Tumors

Authors: Alexia Klonou, Christina Piperi, Antonios N. Gargalionis, Athanasios G. Papavassiliou

Published in: NeuroMolecular Medicine | Issue 2-3/2017

Login to get access

Abstract

Brain tumors emerge as the second commonest type of pediatric solid tumors following hematologic malignancies. Genomic profiling of low- and high-grade gliomas, ependymomas and medulloblastomas has revealed chromosomal abnormalities and specific gene mutations which have been associated with aberrant activation of crucial signal transduction pathways, including mitogen-activated protein kinase, mammalian target of rapamycin and retinoblastoma tumor suppressor signaling. Furthermore, pediatric high-grade gliomas are associated with chromatin remodeling defects and somatic histone gene mutations that affect prognosis. This review provides an update of the molecular and genetic alterations that characterize pediatric brain tumors, and discusses novel therapeutic approaches targeting these abnormalities.
Literature
Antonelli, M., Badiali, M., Moi, L., Buttarelli, F., Baldi, C., Massimino, M., et al. (2015). KIAA1549: BRAF fusion gene in pediatric brain tumors of various histogenesis. Pediatric Blood and Cancer, 62(4), 724–727.PubMedCrossRef
Bandopadhayay, P., Bergthold, G., Nguyen, B., Schubert, S., Gholamin, S., Tang, Y., et al. (2014). BET bromodomain inhibition of MYC-amplified medulloblastoma. Clinical Cancer Research, 20(4), 912–925.PubMedCrossRef
Bautista, F., Paci, A., Minard-Colin, V., Dufour, C., Grill, J., Lacroix, L., et al. (2014). Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatric Blood and Cancer, 61(6), 1101–1103.PubMedCrossRef
Bax, D. A., Mackay, A., Little, S. E., Carvalho, D., Viana-Pereira, M., Tamber, N., et al. (2010). A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clinical Cancer Research, 16(13), 3368–3377.PubMedPubMedCentralCrossRef
Becher, O. J., & Wechsler-Reya, R. J. (2014). Cancer. For pediatric glioma, leave no histone unturned. Science, 346(6216), 1458–1459.PubMedCrossRef
Becker, A., Scapulatempo-Neto, C., Carloni, A., Paulino, A., Sheren, J., Aisner, D., et al. (2015). KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas. Journal of Neuropathology and Experimental Neurology, 74(7), 743–754.PubMedPubMedCentralCrossRef
Bergthold, G., Bandopadhayay, P., Bi, W. L., Ramkissoon, L., Stiles, C., Segal, R. A., et al. (2014). Pediatric low-grade gliomas: How modern biology reshapes the clinical field. Biochimica et Biophysica Acta, 1845(2), 294–307.PubMedPubMedCentral
Bergthold, G., Bandopadhayay, P., Hoshida, Y., Ramkissoon, S., Ramkissoon, L., Rich, B., et al. (2015). Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncology, 17(11), 1486–1496.PubMedPubMedCentralCrossRef
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., et al. (2013). Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discovery, 3(5), 512–519.PubMedPubMedCentralCrossRef
Buccoliero, A. M., Castiglione, F., Degl’Innocenti, D. R., Gheri, C. F., Genitori, L., & Taddei, G. L. (2012). IDH1 mutation in pediatric gliomas: Has it a diagnostic and prognostic value? Fetal and Pediatric Pathology, 31(5), 278–282.PubMedCrossRef
Buczkowicz, P., Hoeman, C., Rakopoulos, P., Pajovic, S., Letourneau, L., Dzamba, M., et al. (2014). Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics, 46(5), 451–456.PubMedPubMedCentralCrossRef
Cin, H., Meyer, C., Herr, R., Janzarik, W. G., Lambert, S., Jones, D. T., et al. (2011). Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathologica, 121(6), 763–774.PubMedCrossRef
Costa, R. M., Federov, N. B., Kogan, J. H., Murphy, G. G., Stern, J., Ohno, M., et al. (2002). Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature, 415(6871), 526–530.PubMedCrossRef
Cruzeiro, G. A., Dos Reis, M. B., Silveira, V. S., Lira, R. C., Carlotti, C. G., Neder, L. et al. (2017). HIF1A is overexpressed in medulloblastoma and its inhibition reduces proliferation and increases EPAS1 and ATG16L1 methylation. Current Cancer Drug Targets. doi:10.​2174/​1568009617666170​315162525.PubMed
Dasgupta, T., & Haas-Kogan, D. A. (2013). The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Frontiers in Oncology, 3. Article 110.
Downing, J. R., Wilson, R. K., Zhang, J., Mardis, E. R., Pui, C. H., Ding, L., et al. (2012). The pediatric cancer genome project. Nature Genetics, 44(6), 619–622.PubMedPubMedCentralCrossRef
Dubuc, A. M., Remke, M., Korshunov, A., Northcott, P. A., Zhan, S. H., Mendez-Lago, M., et al. (2013). Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathologica, 125(3), 373–384.PubMedCrossRef
Fattet, S., Haberler, C., Legoix, P., Varlet, P., Lellouch-Tubiana, A., Lair, S., et al. (2009). Beta-catenin status in paediatric medulloblastomas: Correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. The Journal of Pathology, 218(1), 86–94.PubMedCrossRef
Fontebasso, A. M., Gayden, T., Nikbakht, H., Neirinck, M., Papillon-Cavanagh, S., Majewski, J., et al. (2014a). Epigenetic dysregulation: A novel pathway of oncogenesis in pediatric brain tumors. Acta Neuropathologica, 128(5), 615–627.PubMedPubMedCentralCrossRef
Fontebasso, A. M., Liu, X. Y., Sturm, D., & Jabado, N. (2013). Chromatin remodeling defects in pediatric and young adult glioblastoma: A tale of a variant histone 3 tail. Brain Pathology, 23(2), 210–216.PubMedCrossRef
Fontebasso, A. M., Papillon-Cavanagh, S., Schwartzentruber, J., Nikbakht, H., Gerges, N., Fiset, P. O., et al. (2014b). Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 46(5), 462–466.PubMedPubMedCentralCrossRef
Forshew, T., Tatevossian, R. G., Lawson, A. R., Ma, J., Neale, G., Ogunkolade, B. W., et al. (2009). Activation of the ERK/MAPK pathway: A signature genetic defect in posterior fossa pilocytic astrocytomas. The Journal of Pathology, 218(2), 172–181.PubMedCrossRef
Gajjar, A., Bowers, D. C., Karajannis, M. A., Leary, S., Witt, H., & Gottardo, N. G. (2015). Pediatric brain tumors: Innovative genomic information is transforming the diagnostic and clinical landscape. Journal of Clinical Oncology, 33(27), 2986–2998.PubMedPubMedCentralCrossRef
Gajjar, A., Pfister, S. M., Taylor, M. D., & Gilbertson, R. J. (2014). Molecular insights into pediatric brain tumors have the potential to transform therapy. Clinical Cancer Research, 20(22), 5630–5640.PubMedPubMedCentralCrossRef
Garcia, I., Crowther, A. J., Gama, V., Miller, C. R., Deshmukh, M., & Gershon, T. R. (2013). Bax deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation. Oncogene, 32(18), 2304–2314. doi:10.​1038/​onc.​2012.​248.PubMedCrossRef
Gerges, N., Fontebasso, A. M., Albrecht, S., Faury, D., & Jabado, N. (2013). Pediatric high-grade astrocytomas: A distinct neuro-oncological paradigm. Genome Medicine, 5(7), 66.PubMedPubMedCentralCrossRef
Gielen, G. H., Gessi, M., Hammes, J., Kramm, C. M., Waha, A., & Pietsch, T. (2013). H3F3A K27M mutation in pediatric CNS tumors: A marker for diffuse high-grade astrocytomas. American Journal of Clinical Pathology, 139(3), 345–349.PubMedCrossRef
Gilheeney, S. W., & Kieran, M. W. (2012). Differences in molecular genetics between pediatric and adult malignant astrocytomas: Age matters. Future Oncology, 8(5), 549–558.PubMedCrossRef
Glod, J., Rahme, G., Kaur, H., Raabe, E. H., Hwang, E., & Israel, M. (2016). Pediatric brain tumors: Current knowledge and therapeutic opportunities. Journal of Pediatric Hematology/Oncology, 38(4), 249–260.PubMedPubMedCentralCrossRef
Goldberg, A. D., Banaszynski, L. A., et al. (2010). Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell, 140(5), 678–691.PubMedPubMedCentralCrossRef
Hargrave, D. (2009). Paediatric high and low grade glioma: The impact of tumour biology on current and future therapy. British Journal of Neurosurgery, 23(4), 351–363.PubMedCrossRef
Hassan, B., Akcakanat, A., Holder, A. M., & Meric-Bernstam, F. (2013). Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surgical Oncology Clinics of North America, 22(4), 641–664.PubMedCrossRef
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., et al. (2011). Altered telomeres in tumors with ATRX and DAXX mutations. Science, 333(6041), 425.PubMedPubMedCentralCrossRef
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., et al. (2003). Cancerous stem cells can arise from pediatric brain tumors. Proceedings of the National Academy of Sciences USA, 100(25), 15178–15183.CrossRef
Hernaiz Driever, P., von Hornstein, S., Pietsch, T., Kortmann, R., Warmuth-Metz, M., Emser, A., et al. (2010). Natural history and management of low-grade glioma in NF-1 children. Journal of Neuro-Oncology, 100(2), 199–207.PubMedCrossRef
Hervey-Jumper, S. L., Garton, H. J., Lau, D., Altshuler, D., Quint, D. J., Robertson, P. L., et al. (2014). Differences in vascular endothelial growth factor receptor expression and correlation with the degree of enhancement in medulloblastoma. Journal of Neurosurgery: Pediatrics, 14(2), 121–128.PubMed
Ho, C., Mobley, B., Gordish-Dressman, H., VandenBussche, C., Mason, G., Bornhorst, M., et al. (2015). A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Acta Neuropathologica, 130(4), 575–585.PubMedCrossRef
Hovestadt, V., Jones, D. T., Picelli, S., Wang, W., Kool, M., Northcott, P. A., et al. (2014). Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature, 510(7506), 537–541.PubMedCrossRef
Huillard, E., Hashizume, R., Phillips, J. J., Griveau, A., Ihrie, R. A., Aoki, Y., et al. (2012). Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proceedings of the National Academy of Sciences USA, 109(22), 8710–8715.CrossRef
Huse, J. T., & Rosenblum, M. K. (2015). The emerging molecular foundations of pediatric brain tumors. Journal of Child Neurology, 30(13), 1838–1850.PubMedCrossRef
Jacob, K., Albrecht, S., Sollier, C., Faury, D., Sader, E., Montpetit, A., et al. (2009). Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. British Journal of Cancer, 101(4), 722–733.PubMedPubMedCentralCrossRef
Jacob, K., Quang-Khuong, D. A., Jones, D. T., Witt, H., Lambert, S., Albrecht, S., et al. (2011). Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clinical Cancer Research, 17(14), 4650–4660.PubMedCrossRef
Jones, C., Perryman, L., & Hargrave, D. (2012a). Paediatric and adult malignant glioma: Close relatives or distant cousins? Nature Reviews Clinical Oncology, 9(7), 400–413.PubMedCrossRef
Jones, D. T., Gronych, J., Lichter, P., Witt, O., & Pfister, S. M. (2012b). MAPK pathway activation in pilocytic astrocytoma. Cellular and Molecular Life Sciences, 69(11), 1799–1811.PubMedCrossRef
Jones, D. T., Hutter, B., Jager, N., Korshunov, A., Kool, M., Warnatz, H. J., et al. (2013). Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 45(8), 927–932.PubMedPubMedCentralCrossRef
Jones, D. T., Ichimura, K., Liu, L., Pearson, D. M., Plant, K., & Collins, V. P. (2006). Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. Journal of Neuropathology and Experimental Neurology, 65(11), 1049–1058.PubMedPubMedCentralCrossRef
Jones, D. T., Jager, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., et al. (2012c). Dissecting the genomic complexity underlying medulloblastoma. Nature, 488(7409), 100–105.PubMedPubMedCentralCrossRef
Jones, D. T., Kocialkowski, S., Liu, L., Pearson, D. M., Backlund, L. M., Ichimura, K., et al. (2008). Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Research, 68(21), 8673–8677.PubMedPubMedCentralCrossRef
Jones, D. T., Kocialkowski, S., Liu, L., Pearson, D. M., Ichimura, K., & Collins, V. P. (2009). Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549: BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene, 28(20), 2119–2123.PubMedPubMedCentralCrossRef
Khuong-Quang, D. A., Buczkowicz, P., Rakopoulos, P., Liu, X. Y., Fontebasso, A. M., Bouffet, E., et al. (2012). K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 124(3), 439–447.PubMedPubMedCentralCrossRef
Kieran, M. W., Walker, D., Frappaz, D., & Prados, M. (2010). Brain tumors: From childhood through adolescence into adulthood. Journal of Clinical Oncology, 28(32), 4783–4789.PubMedCrossRef
Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., et al. (2013). Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. Journal of Cell Biology, 201, 511–521.PubMedPubMedCentralCrossRef
Kleinschmidt-DeMasters, B. K., Aisner, D. L., Birks, D. K., & Foreman, N. K. (2013). Epithelioid GBMs show a high percentage of BRAF V600E mutation. The American Journal of Surgical Pathology, 37(5), 685–698.PubMedPubMedCentralCrossRef
Knobbe, C. B., Reifenberger, J., & Reifenberger, G. (2004). Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathologica, 108(6), 467–470.PubMedCrossRef
Krueger, D. A., Care, M. M., Agricola, K., Tudor, C., Mays, M., & Franz, D. N. (2013). Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology, 80(6), 574–580.PubMedPubMedCentralCrossRef
Lassaletta, A., Zapotocky, M., Bouffet, E., Hawkins, C., & Tabori, U. (2016). An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: An update. Childs Nervous System, 32(10), 1789–1797.CrossRef
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., et al. (2014). Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505(7484), 495–501.PubMedPubMedCentralCrossRef
Lin, A., Rodriguez, F. J., Karajannis, M. A., Williams, S. C., Legault, G., Zagzag, D., et al. (2012). BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549: BRAF fusion variants. Journal of Neuropathology and Experimental Neurology, 71(1), 66–72.PubMedPubMedCentralCrossRef
Liu, X. Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D. A., Fontebasso, A. M., et al. (2012). Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathologica, 124(5), 615–625.PubMedCrossRef
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., et al. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica, 114(2), 97–109.PubMedPubMedCentralCrossRef
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., et al. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathologica, 131(6), 803–820.PubMedCrossRef
Mack, S. C., & Northcott, P. A. (2017). Genomic analysis of childhood brain tumors: Methods for genome-wide discovery and precision medicine become mainstream. Journal of Clinical Oncology, 35(21), 2346–2354.PubMedCrossRef
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stutz, A. M., et al. (2014). Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 506(7489), 445–450.PubMedPubMedCentralCrossRef
McLendon, et al. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068.CrossRef
Nicolaides, T. P., Li, H., Solomon, D. A., Hariono, S., Hashizume, R., Barkovich, K., et al. (2011). Targeted therapy for BRAFV600E malignant astrocytoma. Clinical Cancer Research, 17(24), 7595–7604.PubMedPubMedCentralCrossRef
Northcott, P. A., Jones, D. T., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y. J., et al. (2012). Medulloblastomics: The end of the beginning. Nature Reviews Cancer, 12(12), 818–834.PubMedPubMedCentralCrossRef
Northcott, P. A., Lee, C., Zichner, T., Stutz, A. M., Erkek, S., Kawauchi, D., et al. (2014). Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 511(7510), 428–434.PubMedPubMedCentralCrossRef
Northcott, P. A., Pfister, S. M., & Jones, D. T. (2015). Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. The Lancet Oncology, 16(6), e293–e302.PubMedCrossRef
Park, S., Won, J., Kim, S., Lee, Y., Park, C., Kim, S., et al. (2017). Molecular testing of brain tumor. Journal of Pathology and Translational Medicine, 51(3), 205–223.PubMedPubMedCentralCrossRef
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321(5897), 1807–1812.PubMedPubMedCentralCrossRef
Paugh, B. S., Broniscer, A., Qu, C., Miller, C. P., Zhang, J., Tatevossian, R. G., et al. (2011). Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. Journal of Clinical Oncology, 29(30), 3999–4006.PubMedPubMedCentralCrossRef
Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., et al. (2010). Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. Journal of Clinical Oncology, 28(18), 3061–3068.PubMedPubMedCentralCrossRef
Paugh, B. S., Zhu, X., Qu, C., Endersby, R., Diaz, A. K., Zhang, J., et al. (2013). Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Research, 73(20), 6219–6229.PubMedPubMedCentralCrossRef
Penman, C., Faulkner, C., Lowis, S., & Kurian, K. (2015). Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Frontiers in Oncology, eCollection 2015.
Populo, H., Lopes, J. M., & Soares, P. (2012). The mTOR signalling pathway in human cancer. International Journal of Molecular Sciences, 13(2), 1886–1918.PubMedPubMedCentralCrossRef
Puget, S., Philippe, C., Bax, D. A., Job, B., Varlet, P., Junier, M. P., et al. (2012). Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS ONE, 7(2), e30313.PubMedPubMedCentralCrossRef
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., Bochicchio, J., et al. (2012). Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature, 488(7409), 106–110.PubMedPubMedCentralCrossRef
Qu, H. Q., Jacob, K., Fatet, S., Ge, B., Barnett, D., Delattre, O., et al. (2010). Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncology, 12(2), 153–163.PubMedPubMedCentralCrossRef
Raabe, E. H., Lim, K. S., Kim, J. M., Meeker, A., Mao, X. G., Nikkhah, G., et al. (2011). BRAF activation induces transformation and then senescence in human neural stem cells: A pilocytic astrocytoma model. Clinical Cancer Research, 17(11), 3590–3599.PubMedPubMedCentralCrossRef
Ramkissoon, L. A., Horowitz, P. M., Craig, J. M., Ramkissoon, S. H., Rich, B. E., Schumacher, S. E., et al. (2013). Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proceedings of the National Academy of Sciences USA, 110(20), 8188–8193.CrossRef
Rausch, T., Jones, D. T., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., et al. (2012). Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell, 148(1–2), 59–71.PubMedPubMedCentralCrossRef
Reuss, D., & von Deimling, A. (2009). Hereditary tumor syndromes and gliomas. Recent Results in Cancer Research, 171, 83–102.PubMedCrossRef
Robinson, G., Parker, M., Kranenburg, T. A., Lu, C., Chen, X., Ding, L., et al. (2012). Novel mutations target distinct subgroups of medulloblastoma. Nature, 488(7409), 43–48.PubMedPubMedCentralCrossRef
Rodriguez, E. F., Scheithauer, B. W., Giannini, C., Rynearson, A., Cen, L., Hoesley, B., et al. (2011). PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathologica, 121(3), 407–420.PubMedCrossRef
Rosner, M., Hanneder, M., Siegel, N., Valli, A., & Hengstschlager, M. (2008). The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutation Research, 658(3), 234–246.PubMedCrossRef
Roujeau, T., Machado, G., Garnett, M. R., Miquel, C., Puget, S., Geoerger, B., et al. (2007). Stereotactic biopsy of diffuse pontine lesions in children. Journal of Neurosurgery, 107(1 Suppl), 1–4.PubMed
Ryall, S., Krishnatry, R., Arnoldo, A., Buczkowicz, P., Mistry, M., Siddaway, R., et al. (2016). Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathol Commun, 4(1), 93.PubMedPubMedCentralCrossRef
Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M. Y., Yu, M., et al. (2010). Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Research, 70(2), 512–519.PubMedPubMedCentralCrossRef
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., et al. (2011). Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica, 121(3), 397–405.PubMedCrossRef
Schneider, K., Zelley, K., Nichols, K. E., & Garber, J. (2013). Li-Fraumeni Syndrome. In R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, et al. (Eds.), GeneReviews ® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017.
Schwartzentruber, J., Korshunov, A., Liu, X. Y., Jones, D. T., Pfaff, E., Jacob, K., et al. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 482(7384), 226–231.PubMedCrossRef
Segal, D., & Karajannis, M. A. (2016). Pediatric brain tumors: An update. Current Problems in Pediatric and Adolescent Health Care, 46(7), 242–250.PubMedCrossRef
Shih, D. J., Northcott, P. A., Remke, M., et al. (2014). Cytogenetic prognostication within medulloblastoma subgroups. Journal of Clinical Oncology, 32(9), 886–896.PubMedPubMedCentralCrossRef
Sie, M., den Dunnen, W. F., Hoving, E. W., & de Bont, E. S. (2014). Anti-angiogenic therapy in pediatric brain tumors: An effective strategy? Critical Reviews in Oncology Hematology, 89(3), 418–432.CrossRef
Sobol-Milejska, G., Mizia-Malarz, A., Musiol, K., Chudek, J., Bożentowicz-Wikarek, M., Wos, H., et al. (2017). Serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in children with brain tumours. Advances in Clinical and Experimental Medicine. doi:10.​17219/​acem/​62320.PubMed
Staedtke, V., A Dzaye, O. D., & Holdhoff, M. (2016). Actionable molecular biomarkers in primary brain tumors. Trends Cancer, 2(7), 338–349.PubMedCentralCrossRef
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D. A., Jones, D. T., Konermann, C., et al. (2012). Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell, 22(4), 425–437.PubMedCrossRef
Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., et al. (2014). Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine, 20(7), 732–740.PubMedPubMedCentralCrossRef
Tatevossian, R. G., Tang, B., Dalton, J., Forshew, T., Lawson, A. R., Ma, J., et al. (2010). MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathologica, 120(6), 731–743.PubMedPubMedCentralCrossRef
Taylor, K. R., Mackay, A., Truffaux, N., Butterfield, Y. S., Morozova, O., Philippe, C., et al. (2014). Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 46(5), 457–461.PubMedPubMedCentralCrossRef
van Slegtenhorst, M., de Hoogt, R., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., et al. (1997). Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 277(5327), 805–808.PubMedCrossRef
Venneti, S., Garimella, M. T., Sullivan, L. M., Martinez, D., Huse, J. T., Heguy, A., et al. (2013). Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathology, 23(5), 558–564.PubMedCrossRef
Venneti, S., Santi, M., Felicella, M. M., Yarilin, D., Phillips, J. J., Sullivan, L. M., et al. (2014). A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathologica, 128(5), 743–753.PubMedPubMedCentralCrossRef
Waldmann, T., & Schneider, R. (2013). Targeting histone modifications—Epigenetics in cancer. Current Opinion in Cell Biology, 25(2), 184–189.PubMedCrossRef
Wells, E. M., & Packer, R. J. (2015). Pediatric brain tumors. Continuum (Minneap Minn), 21(2 Neuro-oncology), 373–396.
Wu, G., Broniscer, A., McEachron, T. A., Lu, C., Paugh, B. S., Becksfort, J., et al. (2012). Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature Genetics, 44(3), 251–253.PubMedPubMedCentralCrossRef
Wu, G., Diaz, A. K., Paugh, B. S., Rankin, S. L., Ju, B., Li, Y., et al. (2014). The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genetics, 46(5), 444–450.PubMedPubMedCentralCrossRef
Yuen, B. T., & Knoepfler, P. S. (2013). Histone H3.3 mutations: A variant path to cancer. Cancer Cell, 24(5), 567–574.PubMedCrossRef
Zhang, J., Wu, G., Miller, C. P., Tatevossian, R. G., Dalton, J. D., Tang, B., et al. (2013). Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nature Genetics, 45(6), 602–612.PubMedPubMedCentralCrossRef
Metadata
Title
Molecular Basis of Pediatric Brain Tumors
Authors
Alexia Klonou
Christina Piperi
Antonios N. Gargalionis
Athanasios G. Papavassiliou
Publication date
01-09-2017
Publisher
Springer US
Published in
NeuroMolecular Medicine / Issue 2-3/2017
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI
https://doi.org/10.1007/s12017-017-8455-9

Other articles of this Issue 2-3/2017

NeuroMolecular Medicine 2-3/2017 Go to the issue

Review Paper

Invaginating Presynaptic Terminals in Neuromuscular Junctions, Photoreceptor Terminals, and Other Synapses of Animals

Original Paper

An Inframe Trinucleotide Deletion in MTRR Exon 1 is Associated with the Risk of Spina Bifida

Original Paper

Association Between NOS1 Gene Polymorphisms and Schizophrenia in Asian and Caucasian Populations: A Meta-Analysis

Original Paper

Vitamin D3 Reverses the Hippocampal Cytoskeleton Imbalance But Not Memory Deficits Caused by Ovariectomy in Adult Wistar Rats

Original Paper

rs3851179 Polymorphism at 5′ to the PICALM Gene is Associated with Alzheimer and Parkinson Diseases in Brazilian Population

Original Paper

Functional and Molecular Characterization of a Novel Traumatic Peripheral Nerve–Muscle Injury Model